ReviewJournal of genetics and genomics = Yi chuan xue bao2021
COVID-19 mRNA vaccines.
Review in Journal of genetics and genomics = Yi chuan xue bao, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.Journal of medical virology · 2022Pooled it
- Pooled it
- Heat shock protein-mediated remodeling of the bone immune microenvironment: mechanisms and precision therapeutic strategies for osteoporosis.Journal of translational medicine · 2026Review
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines.Cancer cell international · 2026Review
- Pandemic fatigue and associated factors: a meta-analysis using the COM-B model.Frontiers in psychology · 2026Review
- Changes in the monitoring and management of hypertension during the COVID-19 pandemic.BMC public health · 2025Article
- Highly scalable prefusion-stabilized RSV F vaccine with enhanced immunogenicity and robust protection.Nature communications · 2025Article
- Looking beyond the origin of SARS-CoV-2: Significant strategic aspects during the five-year journey of COVID-19 vaccine development.Molecular therapy. Nucleic acids · 2025Review
- Emerging dendrimer-based RNA delivery strategies.Nanomedicine (London, England) · 2025Review
- Development of Plant-Based Multivalent Vaccine Candidates for SARS-CoV-2 and Influenza Virus Using InactivatedVaccines · 2025Article
- Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.Frontiers in oncology · 2025Article
- Comprehensive review on COVID-19: etiology, pathogenicity, and treatment.Frontiers in medicine · 2025Review
- Research and Development of Medical Countermeasures for Emerging Infectious Diseases, China, 1990-2022.Emerging infectious diseases · 2025Article
- SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.PloS one · 2025Article
- How much genetic information in RNA form can be protected by a CCMV virus-like particle?PloS one · 2025Article
- Article
- mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.Science (New York, N.Y.) · 2024Article
- Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity.Nature biomedical engineering · 2024Article
- Delivery of Experimental mRNA Vaccine Encoding the RBD of SARS-CoV-2 by Jet Injection.Bulletin of experimental biology and medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines. Taking substantial advantages of versatility and rapid development, two mRNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive results. In this review, we outline keynotes in mRNA vaccine development, discuss recently published data on COVID-19 mRNA vaccine candidates, focusing on those in clinical trials and analyze future potential challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.